Last $48.20 USD
Change Today +0.75 / 1.58%
Volume 631.8K
CLVS On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

clovis oncology inc (CLVS) Snapshot

Open
$47.31
Previous Close
$47.45
Day High
$48.67
Day Low
$47.07
52 Week High
03/6/14 - $93.33
52 Week Low
08/4/14 - $35.33
Market Cap
1.6B
Average Volume 10 Days
1.0M
EPS TTM
$-3.83
Shares Outstanding
34.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CLOVIS ONCOLOGY INC (CLVS)

clovis oncology inc (CLVS) Related Businessweek News

No Related Businessweek News Found

clovis oncology inc (CLVS) Details

Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. The company has three clinical development programs and one drug discovery program underway. Its clinical development programs include CO-1686, an oral epidermal growth factor receptor and mutant-selective covalent inhibitor, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; rucaparib, an oral inhibitor of poly polymerase that is being explored in Phase II or III clinical trials for treating ovarian cancer patients, and Phase II clinical trials for treating pancreatic cancer patients; and lucitanib, an oral inhibitor of the tyrosine kinase Phase I/IIa clinical trials for the treatment of breast and lung cancers. The company's drug discovery program includes the discovery of cKIT inhibitor targeting resistance mutations for the treatment of GIST, a gastrointestinal cancer. It has license agreements with Advenchen Laboratories LLC, Avila Therapeutics, Inc., and Pfizer Inc.; collaboration and license agreement with Les Laboratoires Servier; a drug discovery collaboration agreement with Array BioPharma Inc.; and a collaboration with Foundation Medicine, Inc. Clovis Oncology, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

74 Employees
Last Reported Date: 02/28/14
Founded in 2009

clovis oncology inc (CLVS) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $924.5K
Co-Founder, Chief Medical Officer and Executi...
Total Annual Compensation: $635.0K
Co-Founder, Chief Regulatory Officer and Exec...
Total Annual Compensation: $592.3K
Co-Founder, Chief Financial Officer, Principa...
Total Annual Compensation: $592.3K
Senior Vice President of Commercial
Total Annual Compensation: $501.4K
Compensation as of Fiscal Year 2013.

clovis oncology inc (CLVS) Key Developments

Clovis Oncology, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Provides Cash Burn Guidance for the Full Year 2014

Clovis Oncology, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company’s loss before income taxes was $39,350,000 compared to $20,320,000 for the same period of last year. Net loss was $39,642,000 compared to $20,320,000 for the same period of last year. Basic and diluted net loss per common share was $1.17 compared to $0.68 for the same period of last year. Operating loss was $41,120,000 compared to $20,375,000 for the same period of last year. Net cash burn for the third quarter of 2014 totaled $35.0 million, and $85.0 million for the first nine months of 2014. For the nine months, the company’s loss before income taxes was $102,635,000 compared to $55,329,000 for the same period of last year. Net loss was $105,124,000 compared to $55,329,000 for the same period of last year. Basic and diluted net loss per common share was $3.10 compared to $2.00 for the same period of last year. Operating loss was $104,569,000 compared to $55,273,000 for the same period of last year. The company continues to expect operating cash burn for 2014 will total approximately $120 million and to end the year with approximately $480 million in cash.

Clovis Oncology Announces First Patient Enrolled in Lucitanib Phase 2 Study in Squamous Non-Small Cell Lung Cancer

Clovis Oncology, Inc. announced that its global Phase 2 study of lucitanib in patients with FGFR1-amplified squamous non-small cell lung cancer (NSCLC) has commenced and the first patient has been dosed at a U.S. study site. Lucitanib is the Company's oral, potent inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors 1 through 3 (FGFR1-3), vascular endothelial growth factor receptors 1 through 3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR -ß). The lucitanib data presented to date in patients with FGF-aberrant breast cancer are very encouraging, and know that FGFR1 amplification occurs in approximately 15% of patients with squamous non-small cell lung cancer. The Phase 2 study will enroll FGFR1-amplified squamous NSCLC patients with advanced disease who have progressed on at least one prior line of therapy. The global study will assess objective response rate, progression-free survival, and duration of response, as well as the safety, tolerability, and pharmacokinetics of lucitanib. Lucitanib is unique among tyrosine kinase inhibitors being developed for cancer therapy, as it effectively targets fibroblast growth factor receptors (FGFR)1-3, vascular endothelial growth factor receptors (VEGFR)1-3, and platelet-derived growth factor receptors (PDGFR) alpha and beta with minimal off-target activity. This selectivity profile allows lucitanib to provide a potential benefit to cancer patients by targeting multiple pathways of tumor development. Specifically, by targeting the FGFR pathway, lucitanib can have a direct antitumor effect in FGF/FGFR driven tumors such as breast or lung cancers harboring amplification of the FGFR1 gene. In addition, by targeting the FGFR, VEGFR and PDGFR receptors lucitanib also can inhibit the development of blood vessels that are required by the tumor to grow and spread. In addition to this Clovis-sponsored Phase 2 study in squamous NSCLC, a global development program for lucitanib in breast cancer is underway, which includes the Clovis-sponsored Phase 2 study in FGF-aberrant advanced breast cancer being conducted in the U.S., the Servier-sponsored FINESSE study of lucitanib monotherapy being conducted in Europe, Canada and Australia as well as the Servier-sponsored INES study evaluating lucitanib in combination with fulvestrant after failure of endocrine therapy.

Clovis Oncology, Inc. to Report Q3, 2014 Results on Nov 06, 2014

Clovis Oncology, Inc. announced that they will report Q3, 2014 results at 4:30 PM, US Eastern Standard Time on Nov 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLVS:US $48.20 USD +0.75

CLVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLVS.
View Industry Companies
 

Industry Analysis

CLVS

Industry Average

Valuation CLVS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 118.1x
Price/Book 4.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 59.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CLOVIS ONCOLOGY INC, please visit www.clovisoncology.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.